| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Protein Biosynthesis | 5 | 2009 | 181 | 0.770 |
Why?
|
| Breast Diseases | 2 | 2016 | 40 | 0.670 |
Why?
|
| Endometrial Neoplasms | 1 | 2017 | 69 | 0.600 |
Why?
|
| Peritoneal Neoplasms | 1 | 2017 | 23 | 0.590 |
Why?
|
| Mesothelioma | 1 | 2017 | 21 | 0.590 |
Why?
|
| RNA, Messenger | 4 | 2009 | 1663 | 0.580 |
Why?
|
| Myocardium | 3 | 2014 | 1204 | 0.480 |
Why?
|
| Proto-Oncogene Proteins c-jun | 3 | 2009 | 71 | 0.450 |
Why?
|
| 5' Untranslated Regions | 2 | 2009 | 16 | 0.410 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2011 | 16 | 0.390 |
Why?
|
| Leiomyoma | 1 | 2011 | 28 | 0.390 |
Why?
|
| Hypercalcemia | 1 | 2011 | 34 | 0.390 |
Why?
|
| Uterine Neoplasms | 1 | 2011 | 99 | 0.390 |
Why?
|
| Fibroblasts | 2 | 2021 | 902 | 0.350 |
Why?
|
| Myocytes, Cardiac | 4 | 2009 | 442 | 0.350 |
Why?
|
| Triple Negative Breast Neoplasms | 2 | 2019 | 41 | 0.340 |
Why?
|
| Lymph Nodes | 2 | 2020 | 258 | 0.330 |
Why?
|
| Hemangiosarcoma | 2 | 2019 | 23 | 0.320 |
Why?
|
| Matrix Metalloproteinase 14 | 1 | 2007 | 44 | 0.300 |
Why?
|
| Ventricular Pressure | 1 | 2007 | 82 | 0.300 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 2007 | 106 | 0.290 |
Why?
|
| Glycation End Products, Advanced | 2 | 2018 | 125 | 0.270 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2006 | 216 | 0.260 |
Why?
|
| Heart Atria | 2 | 2016 | 206 | 0.260 |
Why?
|
| Urinary Bladder | 2 | 2016 | 108 | 0.250 |
Why?
|
| Prostatic Neoplasms | 3 | 2020 | 778 | 0.250 |
Why?
|
| Gene Expression Regulation | 2 | 2007 | 1293 | 0.240 |
Why?
|
| Heart Ventricles | 1 | 2007 | 738 | 0.220 |
Why?
|
| Female | 18 | 2019 | 38015 | 0.220 |
Why?
|
| Proteomics | 2 | 2021 | 246 | 0.210 |
Why?
|
| Humans | 24 | 2021 | 68525 | 0.200 |
Why?
|
| Penile Induration | 1 | 2020 | 2 | 0.190 |
Why?
|
| Scholarly Communication | 1 | 2020 | 2 | 0.190 |
Why?
|
| Endoscopic Ultrasound-Guided Fine Needle Aspiration | 1 | 2020 | 16 | 0.190 |
Why?
|
| Penis | 1 | 2020 | 25 | 0.190 |
Why?
|
| Ossification, Heterotopic | 1 | 2020 | 45 | 0.180 |
Why?
|
| Image-Guided Biopsy | 1 | 2019 | 17 | 0.170 |
Why?
|
| Social Media | 1 | 2020 | 58 | 0.170 |
Why?
|
| Cartilage | 1 | 2019 | 51 | 0.170 |
Why?
|
| Amino Sugars | 1 | 2019 | 12 | 0.170 |
Why?
|
| Lung Neoplasms | 2 | 2020 | 1172 | 0.170 |
Why?
|
| Cats | 3 | 2009 | 292 | 0.170 |
Why?
|
| Lymph Node Excision | 1 | 2019 | 91 | 0.170 |
Why?
|
| Breast Neoplasms | 2 | 2018 | 1533 | 0.170 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2019 | 151 | 0.160 |
Why?
|
| Cancer Care Facilities | 1 | 2018 | 32 | 0.160 |
Why?
|
| Neovascularization, Pathologic | 1 | 2019 | 183 | 0.160 |
Why?
|
| Carcinoma in Situ | 1 | 2018 | 45 | 0.160 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2020 | 284 | 0.160 |
Why?
|
| Receptor, ErbB-2 | 1 | 2019 | 128 | 0.160 |
Why?
|
| Receptors, Estrogen | 1 | 2018 | 142 | 0.160 |
Why?
|
| Biopsy | 4 | 2018 | 539 | 0.160 |
Why?
|
| CD8 Antigens | 1 | 2017 | 25 | 0.160 |
Why?
|
| Leukocyte Common Antigens | 1 | 2017 | 41 | 0.160 |
Why?
|
| Diagnostic Errors | 1 | 2018 | 100 | 0.160 |
Why?
|
| Observer Variation | 1 | 2018 | 330 | 0.150 |
Why?
|
| Forkhead Transcription Factors | 1 | 2017 | 94 | 0.150 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2017 | 91 | 0.150 |
Why?
|
| Adult | 9 | 2020 | 21375 | 0.150 |
Why?
|
| Polyribosomes | 2 | 2007 | 24 | 0.150 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2017 | 33 | 0.150 |
Why?
|
| Collagen | 1 | 2020 | 636 | 0.150 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2017 | 61 | 0.150 |
Why?
|
| Disease-Free Survival | 1 | 2017 | 349 | 0.150 |
Why?
|
| Polysaccharides | 1 | 2019 | 176 | 0.150 |
Why?
|
| Biomedical Research | 1 | 2020 | 310 | 0.140 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2017 | 114 | 0.140 |
Why?
|
| Life Style | 1 | 2018 | 338 | 0.140 |
Why?
|
| Breast Density | 1 | 2016 | 21 | 0.140 |
Why?
|
| Heart Neoplasms | 1 | 2016 | 33 | 0.140 |
Why?
|
| Research Design | 1 | 2020 | 729 | 0.140 |
Why?
|
| Referral and Consultation | 1 | 2018 | 383 | 0.140 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2017 | 235 | 0.130 |
Why?
|
| Eukaryotic Initiation Factor-4E | 2 | 2006 | 19 | 0.130 |
Why?
|
| Middle Aged | 8 | 2020 | 21119 | 0.130 |
Why?
|
| Proportional Hazards Models | 1 | 2017 | 791 | 0.130 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2017 | 265 | 0.130 |
Why?
|
| Nuclear Proteins | 1 | 2017 | 271 | 0.130 |
Why?
|
| Sarcoma, Ewing | 1 | 2015 | 26 | 0.130 |
Why?
|
| Coronary Thrombosis | 1 | 2015 | 45 | 0.130 |
Why?
|
| Urodynamics | 1 | 2015 | 43 | 0.130 |
Why?
|
| Membrane Proteins | 1 | 2019 | 617 | 0.130 |
Why?
|
| Urethra | 1 | 2015 | 56 | 0.130 |
Why?
|
| Prognosis | 2 | 2017 | 2093 | 0.130 |
Why?
|
| Myocarditis | 1 | 2014 | 49 | 0.130 |
Why?
|
| Magnetic Resonance Imaging, Cine | 1 | 2014 | 83 | 0.130 |
Why?
|
| Eosinophilia | 1 | 2014 | 47 | 0.130 |
Why?
|
| Mastocytosis | 1 | 2014 | 6 | 0.120 |
Why?
|
| Animals | 9 | 2019 | 20877 | 0.120 |
Why?
|
| Models, Animal | 1 | 2015 | 252 | 0.120 |
Why?
|
| Apoptosis | 2 | 2019 | 1640 | 0.120 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2013 | 66 | 0.120 |
Why?
|
| Liposarcoma | 1 | 2013 | 13 | 0.120 |
Why?
|
| Inflammasomes | 1 | 2013 | 39 | 0.120 |
Why?
|
| Mammography | 1 | 2016 | 310 | 0.120 |
Why?
|
| Mast Cells | 1 | 2014 | 113 | 0.110 |
Why?
|
| Adenoviridae | 3 | 2009 | 295 | 0.110 |
Why?
|
| Cells, Cultured | 3 | 2007 | 2673 | 0.110 |
Why?
|
| Fibrosis | 3 | 2020 | 371 | 0.110 |
Why?
|
| Receptors, Cell Surface | 1 | 2013 | 248 | 0.110 |
Why?
|
| Diagnosis, Differential | 1 | 2015 | 1139 | 0.110 |
Why?
|
| United States | 3 | 2020 | 7335 | 0.100 |
Why?
|
| Aged | 8 | 2020 | 14842 | 0.100 |
Why?
|
| Parathyroid Hormone-Related Protein | 1 | 2011 | 15 | 0.100 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2014 | 285 | 0.100 |
Why?
|
| Diphosphonates | 1 | 2011 | 39 | 0.100 |
Why?
|
| Gynecologic Surgical Procedures | 1 | 2011 | 37 | 0.100 |
Why?
|
| Cell Proliferation | 2 | 2019 | 1173 | 0.090 |
Why?
|
| Biomarkers, Tumor | 1 | 2014 | 508 | 0.090 |
Why?
|
| Calcitriol | 1 | 2011 | 106 | 0.090 |
Why?
|
| Mediastinum | 2 | 2020 | 39 | 0.090 |
Why?
|
| Transduction, Genetic | 1 | 2009 | 81 | 0.090 |
Why?
|
| Critical Care | 1 | 2011 | 263 | 0.080 |
Why?
|
| Aged, 80 and over | 4 | 2020 | 4843 | 0.080 |
Why?
|
| Neoplasm Grading | 2 | 2018 | 110 | 0.080 |
Why?
|
| Hypertrophy | 1 | 2007 | 89 | 0.080 |
Why?
|
| Peptide Elongation Factor 2 | 1 | 2007 | 14 | 0.080 |
Why?
|
| Vasoconstriction | 1 | 2007 | 81 | 0.080 |
Why?
|
| Intracellular Space | 1 | 2007 | 42 | 0.080 |
Why?
|
| Head and Neck Neoplasms | 1 | 2013 | 561 | 0.080 |
Why?
|
| Organ Size | 1 | 2007 | 242 | 0.080 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2 | 2020 | 306 | 0.070 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2007 | 145 | 0.070 |
Why?
|
| Calcium | 1 | 2011 | 929 | 0.070 |
Why?
|
| Treatment Outcome | 3 | 2018 | 7028 | 0.070 |
Why?
|
| Microscopy, Confocal | 1 | 2007 | 337 | 0.070 |
Why?
|
| RNA Stability | 1 | 2006 | 55 | 0.070 |
Why?
|
| Purkinje Fibers | 1 | 2006 | 20 | 0.070 |
Why?
|
| Aorta | 1 | 2007 | 316 | 0.070 |
Why?
|
| Avian Proteins | 1 | 2006 | 23 | 0.070 |
Why?
|
| Doxorubicin | 1 | 2007 | 231 | 0.070 |
Why?
|
| Mice | 3 | 2019 | 8472 | 0.070 |
Why?
|
| Cell Membrane | 1 | 2007 | 523 | 0.070 |
Why?
|
| Kinetics | 1 | 2007 | 1047 | 0.070 |
Why?
|
| Transcription, Genetic | 1 | 2007 | 562 | 0.070 |
Why?
|
| Severity of Illness Index | 1 | 2011 | 1851 | 0.070 |
Why?
|
| Pregnancy | 1 | 2011 | 2331 | 0.060 |
Why?
|
| Homeodomain Proteins | 1 | 2006 | 157 | 0.060 |
Why?
|
| Infant, Newborn | 1 | 2011 | 2453 | 0.060 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2007 | 626 | 0.060 |
Why?
|
| Ventricular Function, Left | 1 | 2007 | 481 | 0.060 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2006 | 328 | 0.060 |
Why?
|
| Predictive Value of Tests | 2 | 2020 | 1465 | 0.060 |
Why?
|
| Neoplasm Staging | 2 | 2018 | 799 | 0.060 |
Why?
|
| Retrospective Studies | 3 | 2020 | 7264 | 0.050 |
Why?
|
| Male | 7 | 2020 | 37281 | 0.050 |
Why?
|
| Transcription Factors | 1 | 2006 | 753 | 0.050 |
Why?
|
| Cell Differentiation | 1 | 2006 | 1034 | 0.050 |
Why?
|
| Proteome | 1 | 2021 | 87 | 0.050 |
Why?
|
| Collagen Type VIII | 1 | 2020 | 7 | 0.050 |
Why?
|
| Non-Fibrillar Collagens | 1 | 2020 | 9 | 0.050 |
Why?
|
| Collagen Type III | 1 | 2020 | 21 | 0.050 |
Why?
|
| Metaplasia | 1 | 2020 | 27 | 0.050 |
Why?
|
| Hydroxylation | 1 | 2020 | 41 | 0.050 |
Why?
|
| Young Adult | 3 | 2019 | 5708 | 0.050 |
Why?
|
| Proline | 1 | 2020 | 52 | 0.050 |
Why?
|
| Collagen Type IV | 1 | 2020 | 28 | 0.050 |
Why?
|
| Spectroscopy, Fourier Transform Infrared | 1 | 2020 | 72 | 0.050 |
Why?
|
| Mass Spectrometry | 1 | 2021 | 284 | 0.050 |
Why?
|
| Fibrillar Collagens | 1 | 2020 | 49 | 0.050 |
Why?
|
| International Cooperation | 1 | 2020 | 88 | 0.050 |
Why?
|
| Autoantigens | 1 | 2020 | 91 | 0.050 |
Why?
|
| Prostatectomy | 1 | 2020 | 87 | 0.050 |
Why?
|
| Workflow | 1 | 2020 | 100 | 0.040 |
Why?
|
| Collagen Type I | 1 | 2020 | 175 | 0.040 |
Why?
|
| Prostate | 1 | 2020 | 116 | 0.040 |
Why?
|
| Time Factors | 1 | 2007 | 4655 | 0.040 |
Why?
|
| Cell Line, Tumor | 2 | 2018 | 1849 | 0.040 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2019 | 76 | 0.040 |
Why?
|
| Mice, Nude | 1 | 2019 | 294 | 0.040 |
Why?
|
| Cooperative Behavior | 1 | 2020 | 235 | 0.040 |
Why?
|
| Paraffin Embedding | 1 | 2019 | 47 | 0.040 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2019 | 304 | 0.040 |
Why?
|
| Tissue Fixation | 1 | 2019 | 58 | 0.040 |
Why?
|
| Tamoxifen | 1 | 2018 | 62 | 0.040 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2018 | 35 | 0.040 |
Why?
|
| Ultrasonography, Interventional | 1 | 2019 | 119 | 0.040 |
Why?
|
| Amino Acid Sequence | 1 | 2020 | 1082 | 0.040 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2018 | 99 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 1 | 2019 | 852 | 0.040 |
Why?
|
| Neoplasm Proteins | 1 | 2020 | 307 | 0.040 |
Why?
|
| Endosonography | 1 | 2019 | 177 | 0.040 |
Why?
|
| Extracellular Matrix | 1 | 2021 | 493 | 0.040 |
Why?
|
| Biomarkers | 2 | 2018 | 1593 | 0.040 |
Why?
|
| Neoplasm Metastasis | 1 | 2019 | 306 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2020 | 621 | 0.040 |
Why?
|
| Hyperplasia | 1 | 2017 | 89 | 0.040 |
Why?
|
| Radiology | 1 | 2018 | 97 | 0.040 |
Why?
|
| Genetic Testing | 1 | 2018 | 159 | 0.040 |
Why?
|
| Neoplasm Invasiveness | 1 | 2018 | 369 | 0.040 |
Why?
|
| Disease Progression | 1 | 2020 | 1037 | 0.040 |
Why?
|
| Hematemesis | 1 | 2016 | 14 | 0.040 |
Why?
|
| Urothelium | 1 | 2016 | 22 | 0.040 |
Why?
|
| Premenopause | 1 | 2016 | 57 | 0.040 |
Why?
|
| Cancer Survivors | 1 | 2018 | 145 | 0.040 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2018 | 332 | 0.040 |
Why?
|
| Hemoptysis | 1 | 2016 | 28 | 0.040 |
Why?
|
| Lactation | 1 | 2017 | 110 | 0.040 |
Why?
|
| Combined Modality Therapy | 1 | 2018 | 951 | 0.030 |
Why?
|
| Postmenopause | 1 | 2016 | 92 | 0.030 |
Why?
|
| Cadaver | 1 | 2016 | 136 | 0.030 |
Why?
|
| Prevalence | 1 | 2020 | 1609 | 0.030 |
Why?
|
| Urethane | 1 | 2015 | 4 | 0.030 |
Why?
|
| Urination | 1 | 2015 | 19 | 0.030 |
Why?
|
| Anesthetics, Intravenous | 1 | 2015 | 27 | 0.030 |
Why?
|
| Autopsy | 1 | 2014 | 56 | 0.030 |
Why?
|
| Promoter Regions, Genetic | 1 | 2017 | 614 | 0.030 |
Why?
|
| Calcinosis | 1 | 2016 | 241 | 0.030 |
Why?
|
| Fatal Outcome | 1 | 2014 | 164 | 0.030 |
Why?
|
| Electromyography | 1 | 2015 | 184 | 0.030 |
Why?
|
| Pressure | 1 | 2015 | 252 | 0.030 |
Why?
|
| Mice, Transgenic | 1 | 2017 | 1032 | 0.030 |
Why?
|
| Muscle Contraction | 1 | 2015 | 210 | 0.030 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2016 | 333 | 0.030 |
Why?
|
| Neuronal Apoptosis-Inhibitory Protein | 1 | 2013 | 3 | 0.030 |
Why?
|
| Necrosis | 1 | 2014 | 239 | 0.030 |
Why?
|
| Genetic Vectors | 2 | 2006 | 311 | 0.030 |
Why?
|
| Cystitis | 1 | 2013 | 18 | 0.030 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2014 | 282 | 0.030 |
Why?
|
| Glyburide | 1 | 2013 | 19 | 0.030 |
Why?
|
| NLR Family, Pyrin Domain-Containing 3 Protein | 1 | 2013 | 22 | 0.030 |
Why?
|
| Toll-Like Receptors | 1 | 2013 | 56 | 0.030 |
Why?
|
| Salvage Therapy | 1 | 2014 | 82 | 0.030 |
Why?
|
| Cyclophosphamide | 1 | 2013 | 129 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2014 | 507 | 0.030 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2013 | 125 | 0.030 |
Why?
|
| Immunity, Innate | 1 | 2013 | 156 | 0.030 |
Why?
|
| Phosphorylation | 2 | 2007 | 1199 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2013 | 536 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2014 | 1174 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2018 | 3256 | 0.030 |
Why?
|
| Contrast Media | 1 | 2014 | 594 | 0.020 |
Why?
|
| Adenocarcinoma | 1 | 2014 | 475 | 0.020 |
Why?
|
| Carrier Proteins | 1 | 2013 | 597 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2015 | 2083 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2018 | 2688 | 0.020 |
Why?
|
| Risk Factors | 1 | 2018 | 5719 | 0.020 |
Why?
|
| CASP8 and FADD-Like Apoptosis Regulating Protein | 1 | 2007 | 18 | 0.020 |
Why?
|
| X-Linked Inhibitor of Apoptosis Protein | 1 | 2007 | 17 | 0.020 |
Why?
|
| Protein Synthesis Inhibitors | 1 | 2007 | 32 | 0.020 |
Why?
|
| Free Radicals | 1 | 2007 | 65 | 0.020 |
Why?
|
| Iron Chelating Agents | 1 | 2007 | 31 | 0.020 |
Why?
|
| Deferoxamine | 1 | 2007 | 45 | 0.020 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 1 | 2007 | 65 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2016 | 2222 | 0.020 |
Why?
|
| Drug Synergism | 1 | 2007 | 260 | 0.020 |
Why?
|
| Hydrogen Peroxide | 1 | 2007 | 168 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2014 | 1070 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2016 | 2323 | 0.020 |
Why?
|
| Connexins | 1 | 2006 | 35 | 0.020 |
Why?
|
| Cell Cycle | 1 | 2007 | 312 | 0.020 |
Why?
|
| Myosin Heavy Chains | 1 | 2006 | 49 | 0.020 |
Why?
|
| Rats | 1 | 2013 | 5300 | 0.020 |
Why?
|
| Chick Embryo | 1 | 2006 | 379 | 0.020 |
Why?
|
| Cell Nucleus | 1 | 2006 | 305 | 0.020 |
Why?
|
| Phenotype | 1 | 2007 | 946 | 0.020 |
Why?
|
| Nucleic Acid Conformation | 1 | 2004 | 92 | 0.010 |
Why?
|
| Genes, Reporter | 1 | 2004 | 191 | 0.010 |
Why?
|
| Child | 1 | 2013 | 6400 | 0.010 |
Why?
|
| Adolescent | 1 | 2013 | 8903 | 0.010 |
Why?
|